Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when UFPT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsUFP Technologies files investor presentation with 12–18% annual revenue growth target
Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
high
Company sets 3–5 year targets: 12–18% annual revenue growth, 28–31% gross margins, and 17–20% adjusted operating margins, signaling management's confidence in sustained expansion.
Exhibit 99.1 view on EDGAR → -
high
2025 revenue reached $603M with 17.1% adjusted operating margin and 28.6% gross margin, representing 3.4× growth from 2020.
Exhibit 99.1 view on EDGAR → -
medium
Presentation outlines addressable market of ~$518B global medical device market (6.3% CAGR) with ~$100B outsourcing opportunity (10% CAGR).
Exhibit 99.1 view on EDGAR → -
low
Updated investor presentation materials filed for use in meetings and presentations under Regulation FD.
Item 7.01 verify on EDGAR →
Summary
UFP Technologies filed updated investor presentation materials that establish formal 3–5 year financial targets for the first time: 12–18% annual revenue growth, 28–31% gross margins, and 17–20% adjusted operating margins. The company positions itself as a contract development and manufacturing organization (CDMO) serving the medical device and sterile packaging markets, with 2025 revenue of $603 million and current market capitalization of approximately $1.7 billion as of June 2, 2026. The presentation frames UFP's growth strategy around a ~$100 billion outsourcing opportunity within the broader ~$518 billion global medical device market, with exposure to high-growth segments including robotic-assisted surgery (13–17% CAGR) and cardiovascular devices (6.5–7% CAGR).
Management's multi-year targets signal confidence in sustaining the 3.4× revenue expansion achieved from 2020 to 2025 through a combination of organic growth and customer-centric acquisitions. The filing is a routine Regulation FD disclosure to ensure material information shared in investor meetings is publicly available.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
UFP Technologies, Inc. (the “Company”) has attached hereto as Exhibit 99.1 a copy of updated presentation materials concerning its business that it intends to use in connection with meetings with investors and other interested parties and in connection with presentations and speeches to various audiences.
The company filed updated presentation materials as Exhibit 99.1 for use in investor meetings and presentations. This is a routine disclosure under Regulation FD to ensure material information is publicly available when shared with select audiences.
Event · Exhibit 99.1
UFP Technologies filed an investor presentation deck outlining its business model, market opportunity, and financial targets.
Added in current filing · view on EDGAR →
UFP Technologies is a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products.
The company filed an investor presentation deck describing its business as a contract development and manufacturing organization (CDMO) focused on medical devices and sterile packaging. The presentation outlines the company's market position, competitive advantages, and growth strategy. This type of filing typically accompanies investor meetings or conferences and provides updated messaging on the company's strategic positioning.
Added in current filing · view on EDGAR →
$603M Revenue (2025)
The presentation discloses 2025 revenue of $603 million with an adjusted operating margin of 17.1% and gross margin of 28.6%. This represents 3.4× revenue growth from 2020 to 2025. The company's current market capitalization is approximately $1.7 billion as of June 2, 2026.
Added in current filing · view on EDGAR →
~$518B Global Medical Device Market ~6.3% CAGR1 ~$100B Outsourcing Opportunity ~10% CAGR2
The presentation outlines UFP's addressable market as a ~$518 billion global medical device market growing at approximately 6.3% CAGR, with a ~$100 billion outsourcing opportunity growing at approximately 10% CAGR. The company focuses on growth segments including Robotic Assisted Surgery (13-17% CAGR), Infection Control (5.5-6.5% CAGR), and Cardiovascular (6.5-7% CAGR), among others.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 12, 2026 · How we verify